Sibylle F. Loibl
Advanced in Metastatic Brain Tumor

Sibylle F. Loibl

Martin Behaim Str 12, 
Neu Isenburg, HE, DE 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Metastatic Brain Tumor
Martin Behaim Str 12, 
Neu Isenburg, HE, DE 
OverviewLocationsClinical Research

Overview

Sibylle Loibl practices in Neu Isenburg, Germany. Ms. Loibl is rated as an Advanced expert by MediFind in the treatment of Metastatic Brain Tumor. Her top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Breast Cancer in Men, Agranulocytosis, and Mastectomy.

Her clinical research consists of co-authoring 481 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 3 articles in the study of Metastatic Brain Tumor.

Gender
Female

Locations

Martin Behaim Str 12, Neu Isenburg, HE 63263, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Prospective and Retrospective Register Study of the German Breast Group (GBG) for Diagnosis and Treatment of Breast Cancer in Pregnancy
Prospective and Retrospective Register Study of the German Breast Group (GBG) for Diagnosis and Treatment of Breast Cancer in Pregnancy
Enrollment Status: Recruiting
Publish Date: April 17, 2024
An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments
An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments
Enrollment Status: Completed
Publish Date: June 15, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-blind, Phase II Study to Evaluate the Tolerability of an Induction Dose Escalation of Everolimus in Patients With Metastatic Breast Cancer
A Multicenter, Randomized, Double-blind, Phase II Study to Evaluate the Tolerability of an Induction Dose Escalation of Everolimus in Patients With Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: February 23, 2022
Intervention Type: Drug
Study Drugs: Everolimus, Standard Care
Study Phase: Phase 2
A Randomized Phase II Study to Investigate the Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Containing Chemotherapy in Triple Negative Breast Cancer (GeparNuevo)
A Randomized Phase II Study to Investigate the Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Containing Chemotherapy in Triple Negative Breast Cancer (GeparNuevo)
Enrollment Status: Completed
Publish Date: February 15, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Prospective, Randomised, Multi-centre Phase II Study Evaluating the Adjuvant, Neoadjuvant or Palliative Treatmant With Tamoxifen +/- GnRH Analogue Versus Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients
A Prospective, Randomised, Multi-centre Phase II Study Evaluating the Adjuvant, Neoadjuvant or Palliative Treatmant With Tamoxifen +/- GnRH Analogue Versus Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients
Enrollment Status: Completed
Publish Date: September 19, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 4 Less Clinical Trials

481 Total Publications

AGO Breast Commission recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2025.
AGO Breast Commission recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2025.
Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Published: September 09, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Loibl's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 16 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile